Showing results (261-270 of 346) with videos related to

Sort By:
Pageof 35
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Advances|May 13, 2020
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantationMonzr M Al Malki, Dongyun Yang, Myriam Labopin, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Blood Advances|September 13, 2018
Is a matched unrelated donor search needed for all allogeneic transplant candidates?Stefan O Ciurea, Maria Cecilia Borges Bittencourt, Denái R Milton, et al.
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
JAMA|March 7, 2023
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantLaura W Dillon, Gege Gui, Kristin M Page, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Pageof 35